Abstract
Berberine is an isoquinoline alkaloid with multiple pharmacological actions, including anti-inflammatory activity. The aims of this study were to examine the effect of berberine on the mucosal healing process and to investigate whether berberine can inhibit the increased production of interleukin-8 in trinitrobenzene sulfonic acid-induced colitis in rats. Berberine was administered orally for 3 days or 1 week at a dosage of 7.5 or 15 mg/kg/day. Tissue damage scores, body weight, colon wet weight, and colon wall thickness were measured, and myeloperoxidase activity in colon tissue was also examined. Histological lesions, morphological damage, and myeloperoxidase activity were reduced after 1 week of treatment with berberine at a dosage of 15 mg/kg/day. Furthermore, 1 week after trinitrobenzene sulfonic acid treatment, the production of interleukin-8 by cultured rectal mucosa or cardiac blood mononuclear cells with or without stimulation of lipopolysaccharide for 24 h was also analyzed by enzyme-linked immunosorbent assay. Cardiac blood mononuclear cells and rectal mucosa of normal rats produced substantial amounts of interleukin-8, which increased strikingly with the stimulation of lipopolysaccharide. Cardiac blood mononuclear cells and rectal mucosa of trinitrobenzene sulfonic acid-treated rats secreted more interleukin-8 than those of normal rats. The addition of berberine with a concentration of 10−5 M to the culture media resulted in an inhibition of interleukin-8 production of rectal mucosa.
Footnotes
-
Send reprint requests to: Dr. Satoru Mineshita, Department of Preventive Medicine, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima Bunkyo-Ku, Tokyo 113-8510, Japan. E-mail: satoru-mineshita.prm{at}mri.tmd.ac.jp
- Abbreviations:
- TNB
- trinitrobenzene sulfonic acid
- IBD
- inflammatory bowel disease
- MPO
- myeloperoxyidase
- LPS
- lipopolysaccharide
- CBMC
- cardiac blood mononuclear cell
- IL
- interleukin
- Received March 6, 2000.
- Accepted May 15, 2000.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|